Skip to main content
. 2017 Mar 1;8:14447. doi: 10.1038/ncomms14447

Figure 3. IFN-I was essential for arenavirus-induced tumour regression.

Figure 3

(a) Immunofluorescence (day 10) of tumours from MOPC-tumour-bearing C57BL/6 mice (day −10) treated with or without 2 × 104 PFU LCMV peritumourally (n=3/group). Scale bar, 200 μm. (b) Immunohistochemistry of dLNs from MOPC-tumour-bearing mice treated with 2 × 104 PFU LCMV subcutaneously (n=3/group). Scale bar, 200 μm. (c) Representative FACS blots (day 2) from dLNs of MOPC-tumour-bearing C57BL/6 mice (day −3) and IFN-β-reporter mice (IFNβmob/mob) treated with 2 × 104 PFU LCMV peritumourally (day 0, n=4 per group). Grey area indicates isotype control. (d) qRT–PCR analysis of dLNs (day 3) from MOPC-tumour-bearing C57BL/6 mice (day −3) treated with or without 2 × 104 PFU LCMV peritumourally (n=3 per group). (e) IFN-α serum ELISA (day 3) from MOPC-tumour-bearing C57BL/6 mice (day −3) treated with or without 2 × 104 PFU LCMV (n=4 per group). (f) Tumour diameters of MOPC-tumour-bearing C57BL/6 mice (day −3) injected with or without anti-Ly6C+G antibody (200 μg, days −2, 2 and 7) and treated with (n=6 per group) or without (n=6 control; n=7 anti-Ly6C+G-dep.) 2 × 104 PFU LCMV peritumourally (two experiments pooled). (g) Tumour diameters of MOPC-tumour-transplanted WT and Ccr2–/– mice (day −3) treated with (n=9 per group) or without (n=6 per group) 2 × 104 PFU LCMV peritumourally (two experiments pooled). (h) Tumour diameter from MOPC-tumour-bearing WT and Irf3–/– x Irf7–/– mice (day × 3) treated with or without 2 × 104 PFU LCMV peritumourally (n=6 per group, two experiments pooled). Data are shown as mean±s.e.m. and analysed by unpaired Student's t-test. Survival is shown in Kaplan–Meier method and analysed by log-rank test. NS, nonsignificant; *P<0.05, **P<0.01 and ***P<0.001.